These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3478081)

  • 21. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
    J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoradiometric assay for CA125 in monitoring the course of epithelial ovarian cancer.
    Tommasi M; Cappelli G; Fantappiè B; Cefaratti C; Bonazza M; Branconi F
    J Nucl Med Allied Sci; 1986; 30(1):45-50. PubMed ID: 3462354
    [No Abstract]   [Full Text] [Related]  

  • 23. Elevation of CA 125 in patients with benign and malignant ascites.
    Bergmann JF; Bidart JM; George M; Beaugrand M; Levy VG; Bohuon C
    Cancer; 1987 Jan; 59(2):213-7. PubMed ID: 3026603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective study of serum CA-125 levels as markers of ovarian cancer.
    Helzlsouer KJ; Bush TL; Alberg AJ; Bass KM; Zacur H; Comstock GW
    JAMA; 1993 Mar; 269(9):1123-6. PubMed ID: 8433467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian cancer screening.
    van Nagell JR; DePriest PD; Gallion HH; Pavlik EJ
    Cancer; 1993 Feb; 71(4 Suppl):1523-8. PubMed ID: 8431889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays.
    Ward BG; McGuckin MA; Ramm LE; Coglan M; Sanderson B; Tripcony L; Free KE
    Cancer; 1993 Jan; 71(2):430-8. PubMed ID: 8422635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
    Kobayashi H; Terao T; Kawashima Y
    J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
    J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
    Kramer BS; Gohagan J; Prorok PC; Smart C
    Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effectiveness of ovarian cancer screening. A decision analysis model.
    Schapira MM; Matchar DB; Young MJ
    Ann Intern Med; 1993 Jun; 118(11):838-43. PubMed ID: 8480957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125.
    Sevelda P; Dittrich C; Salzer H; Pateisky N; Spona J
    Cancer Detect Prev; 1986; 9(5-6):521-8. PubMed ID: 3465442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for early ovarian cancer.
    Bourne TH; Hampson J; Reynolds K; Collins WP; Campbell S
    Br J Hosp Med; 1992 Oct 21-Nov 3; 48(8):454-9. PubMed ID: 1422556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for ovarian cancer. Multiple markers may outperform CA 125 alone.
    Bast R; Woolas R
    BMJ; 1993 Jun; 306(6893):1684-5. PubMed ID: 8324445
    [No Abstract]   [Full Text] [Related]  

  • 34. Screening for ovarian cancer: not worthwhile for most patients.
    Wong JG; Feussner JR
    N C Med J; 1993 Sep; 54(9):438-40. PubMed ID: 8232615
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumour-associated antigen CA 125 in patients with ovarian cancer.
    Heinonen PK; Tontti K; Koivula T; Pystynen P
    Br J Obstet Gynaecol; 1985 May; 92(5):528-31. PubMed ID: 3857939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
    Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA 15-3 serum levels in ovarian cancer.
    Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S
    Oncology; 1988; 45(3):263-7. PubMed ID: 3163419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology and screening of ovarian cancer.
    Tortolero-Luna G; Mitchell MF; Rhodes-Morris HE
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):1-23. PubMed ID: 8015758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Personalizing ovarian cancer screening.
    Goozner M
    J Natl Cancer Inst; 2010 Aug; 102(15):1112-3. PubMed ID: 20668268
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.